2020 - Olof Johnell Science Award, International Osteoporosis Foundation
1963 - Fellow of the American Association for the Advancement of Science (AAAS)
His primary areas of investigation include Osteoporosis, Bone mineral, Internal medicine, Bone remodeling and Urology. His Osteoporosis study combines topics in areas such as Placebo and Surgery. His work in Bone mineral covers topics such as Dentistry which are related to areas like Risedronate Sodium, Hip bone, Observational study and Medical laboratory.
His Internal medicine study integrates concerns from other disciplines, such as Endocrinology and Physical therapy. His work deals with themes such as Randomized controlled trial and Bone resorption, which intersect with Bone remodeling. His work carried out in the field of Bone density brings together such families of science as Postmenopausal women and Denosumab.
Michael R. McClung spends much of his time researching Osteoporosis, Internal medicine, Bone mineral, Bone density and Endocrinology. His biological study spans a wide range of topics, including Placebo, Surgery, Bone remodeling and Urology. His Surgery study incorporates themes from Ibandronic acid, Bisphosphonate, Tolerability and Hip fracture.
He focuses mostly in the field of Bone mineral, narrowing it down to matters related to Femoral neck and, in some cases, Risedronic acid and Adverse effect. His Bone density research includes elements of Physical therapy, Menopause, Nuclear medicine and Risk factor. In general Endocrinology, his work in Alendronic acid is often linked to Context linking many areas of study.
Michael R. McClung mainly investigates Osteoporosis, Internal medicine, Bone mineral, Denosumab and Placebo. The study incorporates disciplines such as Physical therapy, Incidence and Bone remodeling in addition to Osteoporosis. His Internal medicine research incorporates themes from Endocrinology and Oncology.
His study in Bone mineral is interdisciplinary in nature, drawing from both Urology, Post-hoc analysis, Prospective cohort study, Parathyroid hormone and Cohort. His studies deal with areas such as Discontinuation and Osteonecrosis of the jaw as well as Denosumab. His Placebo research incorporates elements of Femur, Surgery, Phases of clinical research, Meta-analysis and Lumbar vertebrae.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings;Javier San Martin;Michael R. Mcclung;Ethel S. Siris.
The New England Journal of Medicine (2009)
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
Michael R. McClung;Piet Geusens;Paul D. Miller;Hartmut Zippel.
The New England Journal of Medicine (2001)
Primer on the metabolic bone diseases and disorders of mineral metabolism
John P. Bilezikian;Roger Bouillon;Thomas Clemens;Juliet Compston.
Papagerakis, P; Mitsiadis, T A (2008). Primer on the metabolic bone diseases and disorders of mineral metabolism. In: Rosen, Clifford J; Compston, Juliet E; Lian, Jane B. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Washington, DC: John Wiley & Sons, 491-496. (2013)
Denosumab in Postmenopausal Women with Low Bone Mineral Density
Michael R. McClung;E. Michael Lewiecki;Stanley B. Cohen;Michael A. Bolognese.
The New England Journal of Medicine (2006)
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
Samuel Vasikaran;Samuel Vasikaran;Richard Eastell;O. Bruyere;A. J. Foldes.
Osteoporosis International (2011)
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
Michael R. McClung;Andreas Grauer;Steven Boonen;Michael A. Bolognese.
The New England Journal of Medicine (2014)
American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis — 2016
Pauline M. Camacho;Steven M. Petak;Neil Binkley;Dima L. Diab.
Endocrine Practice (2016)
The 2017 hormone therapy position statement of The North American Menopause Society.
Jo Ann V. Pinkerton;Fernando Sánchez Aguirre;Jennifer Blake;Felicia Cosman.
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003.
Stephen F. Hodgson;Nelson B. Watts;John P. Bilezikian;Bart L. Clarke.
Endocrine Practice (2003)
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.
Anthony B. Hodsman;Douglas C. Bauer;David W. Dempster;Larry Dian.
Endocrine Reviews (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: